

# Version 11.0 16 December 2024

# Stichting EuroQol Research Foundation POLICY PLAN



## 1. Introduction

This is the Policy Plan of the Stichting EuroQol Research Foundation (the "Foundation").

This Policy Plan gives an overview of:

- 2) Background, Mission and Vision of the Foundation;
- 3) Activities, organisation and policy;
- 4) Current projects;
- 5) The source, management and use of its funds;
- 6) Testimonials, and
- 7) Contact details.

The Foundation has been granted the status of Charitable Institution, in Dutch Algemeen Nut Beogende Instelling (ANBI), since January 1st, 2014, RSIN: 804679101.

On behalf of the Foundation,

Nancy J Devlin Board Chair

Rotterdam, 16 December 2024



# 2. Background and objectives of the Foundation

The Foundation was established in 1995. The Vision of the Foundation is:

To serve the public benefit, and without an aim for profit, to improve decisions about health and health care throughout the world by developing, making available and supporting the use of instruments with the widest possible applicability for the measurement and valuation of health.

The Foundation is charged with governing the intellectual property rights of the EQ-5D questionnaire and related instruments. Furthermore, its aim is to dedicate at least 90% of its resources to the achievement of its public good mission, including advancing scientific research on health outcomes, supporting health system users to use its questionnaires to measure outcomes and education and outreach activities.

The EuroQol Group Association (the "EuroQol Group") comprises of a network of international, multilingual, multidisciplinary researchers, originally from seven centres in England, Finland, the Netherlands, Norway and Sweden. The EuroQol Group has the same Vision as the Foundation. Currently there more than 120 members worldwide. The process of shared developments, local experimentation and a lively scientific discussion resulted in the EQ-5D questionnaire, a measure generating a single index value for a health status, which is used in health care evaluation, population health surveys and routine measurement of patient-reported outcomes.

Reflecting decades of funding research and development by the Foundation, the EQ-5D questionnaire is now part of a wider family of instruments developed by the Foundation for measuring health (EQ-5D-3L, EQ-5D-5L), and health and wellbeing (EQ-HWB, EQ-HWB-S) in adults; and health in children (EQ-5D-Y-3L, EQ-5D-Y-5L and EQ-TIPS). These instruments are widely used in many countries around the world: the EQ-5D is the most widely recommended, and in some countries even required, instrument for use in Health Technology Appraisal by health care systems around the world. The instruments are available in multiple modes of administration and have been translated into most major languages. Our instruments are accompanied by social preference weights that allow quality adjusted life years (QALYs) to be calculated for use in economic evaluation of health care.

The Mission of the Foundation is to, on a non-profit basis:

- To achieve social good by making available and supporting the use of EuroQol's instruments to improve health care decision-making and health outcomes across the world;
- 2. To provide leadership and innovation in the development of EuroQol's instruments and methods for measuring, valuing, and reporting health;
- 3. To actively transfer knowledge and best practice in the use of EuroQol's instruments;
- 4. To build research capacity by fostering an international community of researchers to sustain and advance the development and application of EuroQol's instruments.



# 3. Activities, organisation and policy

The Foundation and the EuroQol Group are the two arms of the EuroQol organization. The Foundation exists to serve the public benefit by supporting, instigating and performing scientific research. As mentioned above, the EuroQol Group is comprised of an international network of multidisciplinary researchers and has more than 120 members.

The Board of the Foundation has a responsibility for topics such as:

- Strategic thinking about the Foundation's activities, and in particular ensuring the long-term sustainability of the Foundation;
- Ensuring that the overall activities of the Foundation satisfy the requirements of the Foundation's designation as Charitable Institution, in Dutch Algemeen Nut Beogende Instelling (ANBI), e.g., at least 90% of the efforts of the Foundation are to be focused on the public benefit, consistent with the Foundation's stated mission/vision;
- Ensuring the effective and efficient management of all aspects of the Foundation's operations, including governance of the intellectual property rights that include, but are not limited to, EQ-5D. The Board is the employer of the staff in the EuroQol office, including the Executive Director.

The EuroQol Group's Executive Committee can be thought of as the principal 'scientific committee' of the EuroQol Group. The Executive Committee comprises nine members, who are elected by the members of the EuroQol Group. Important roles of the Executive Committee include the appraisal of research proposals, scientific working groups, the organization of the scientific annual meeting and implementing the rules concerning membership of the EuroQol Group.


The Board is entitled to accept (and refuse) donations on behalf of the Foundation. No donations are accepted that are made under known conditions contrary to the mission of the Foundation.

The Executive Director and his staff of scientists and legal/administrative people are based at the EuroQol office in Rotterdam, the Netherlands. The scientists also provide assistance to users of EQ-5D and to scientists involved in studies funded by the Foundation. The legal/administrative team arranges the licensing of EQ-5D. More information on the activities of the Office team can be found on the website.

In the diagram on the next page the EuroQol organisational chart is shown:



# 





# 4. Pending, Current and future projects

In order to achieve its stated objectives, the Foundation supports a substantial programme of research projects. These research projects typically involve methodological research such as the following:

Value sets: EQ-5D is used to measure health-related quality of life in patients in a manner that can be summarised by a value. A societal 'value set study' is conducted to estimate how the general population in a given country values health. These values are widely used around the world in the cost effectiveness analysis of health care technologies, improving decisions about new technologies, helping governments to manage and prioritise health care spending. The Foundation fully funds or co-funds many such value set studies.

Research on valuation methodology: The methodology regarding how to conduct value set studies and how to analyse and model such data is a research discipline in which the Foundation funds a substantial number of studies. These studies have value beyond the EQ-5D questionnaire as the methodology developed may apply also to other questionnaires, such as EQ-HWB and EQ-TIPS.

EQ-5D for children and adolescents: For children and adolescents a special version of EQ-5D, the EQ-5D-Y-3L, has been developed. Research continues on both the questionnaire itself and value sets. For EQ-5D-Y-3L a valuation methodology has been published, which has now been used to produce value sets in close to 20 countries around the world. A 5-level version of the Youth instrument (EQ-5D-Y-5L) was launched in 2024 as an Approved version. Experimental instruments are also being developed and tested for very young infant and toddler populations (EQ-TIPS). Together, these questionnaires will lead to substantial improvements in the evidence available to support health care decisions in paediatrics.

EQ-5D in PROMs research: EQ-5D is used frequently in large surveys as so-called Patient Reported Outcome Measures (PROMs) in healthcare. It provides a quick and simple indication of a patient's health-related quality of life. The Foundation is interested in research on the performance of EQ-5D in PROMs and in research on patient norm data of EQ-5D. These studies provide important information on the burden of disease and the performance of health care services in improving patient health.

EQ-HWB: Several years ago, researchers from the University of Sheffield, in collaboration with an international team of researchers from the EuroQol Group and other organisations, started a research project to produce a self-reported outcome measure, suitable for use across health care and social care. The new instrument is titled EQ-HWB (EQ Health and Wellbeing instrument). EQ-HWB development work is ongoing, including exploration of value sets.

In the financial year 2023-2024 the Foundation funded a total of 85 scientific studies, with a total value of 5,649,071 euros. Studies typically run for 2 to 3 years. As of September 2023, the current number of studies actively underway is 401<sup>1</sup>.

Further information about projects and the activities of the Foundation can be found on its website: <a href="https://euroqol.org/research/">https://euroqol.org/research/</a>.

<sup>&</sup>lt;sup>1</sup> Status 30JUN2024, at the end of the financial year.



# 5. Source, management and use of Funds

The Foundation receives sponsorships/ license fees only from commercial users of EQ-5D. The Board reviews the licensing policy annually. As of 18<sup>th</sup> January 2019, no fees are charged for any non-commercial use of EQ-5D, small or country-wide. Sponsorship/license fees are currently the only source of funding of the Foundation. In the past the Foundation has successfully applied for national- and EU grants, when these grants aligned with the overall research strategy.

Non-commercial organizations, such as universities or hospitals, that want to use EQ-5D can use the instrument free of charge. In the past financial year 2023-2024 the Foundation received 7,584 requests for using EQ-5D. These requests came in from all over the world. Most requests came from the United Kingdom, the United States, Germany, Australia, Japan, the Netherlands, Canada, China, India and France. EQ-5D use is for free for all non-commercial users, and in most cases a license agreement is not needed after registration: 5,140 users were provided with EQ-5D after agreeing to our Terms of Use. Only for very large projects or studies is a licence agreement is needed: 145 non-commercial license agreements were set up for free use. For commercial users 622 paid license agreements were set up, which is 11% of the total volume.

It is difficult to forecast the volume of sponsorships that the Foundation will receive in future years. For several years a steady and strong growth was seen, followed by year of stabilisation, or even decline. In the past 2 years a decline was noted. In financial year 2022-2023 the number of requests for using EQ-5D stayed about the same, while income dropped by 6%. In financial year 2023-2024 the number of requests grew by 10%, while income dropped by 11%

Currently, the paid use of EQ-5D is driven primarily by the fact that EQ-5D is recommended-and in some countries even required in government guidelines on cost-effectiveness analysis in several countries. Changes in such documents would have an effect on the income of the Foundation. In January 2022 the National Institute of Health and Care Excellence (NICE) in England updated its Methods Guide, which continues to state that the EQ-5D measurement method is preferred to measure health-related quality of life in adults. The EQ-5D-3L version and value set still are the reference case for England. If data were gathered using the EQ-5D-5L version, utility values in reference-case analyses should be calculated by mapping the 5L descriptive system data onto the 3L valuation set. This and similar statements may directly affect sponsorship income. In financial year 2021/22, the Foundation funded an important large project, in collaboration with NICE, to produce UK value set for the EQ-5D-5L, which will be completed in 2025.

In the current financial year (2024-2025), the Foundation expects to obtain the same level of sponsorship income as in 2023-2024, although there are signs suggesting the demand for EQ-5D will increase. In years thereafter the Foundation expects to see a slow, gradual increase of funding, perhaps at a slower pace than the past years, unless there is a dramatic change in government guidelines documents.

The Foundation aims to make the instrument available (to non-commercial and commercial users) and support research projects as much as possible towards realising its objectives, whilst



maintaining sufficient reserves to guarantee the continuity of the organisation. Please see the <u>investment policy</u> on how reserves are managed.

Funding scientific research on instruments that describe and value health is one of the key objectives of the Foundation. Members of the EuroQol Group, and non-members, can apply for research (co-)funding. There are two calls for research proposals each year, which are open to applications from both members and non-members. The Executive Committee reviews these applications. Only those applications that show scientific rigour and alignment with the overall research strategy are considered eligible for funding.

The Foundation also funds PhD projects and educational and travel grants. In financial year 2020-2021 8 PhD projects were funded. In financial year 2021-2022 3 PhD projects were funded. In 2022-2023 3 PhD projects were funded and 2 postdoc projects. No new PhD projects were funded in financial year 2023-2024. Given sufficient budget, these educational activities may be expanded in future.

Lastly, in line with our Vision and Mission, the Foundation funded scientific meetings for a total cost of €1,748,613. These meetings were well attended by both members and non-members of the EuroQol Group. The meetings act as the principal opportunity to debate research methods and applications of the questionnaires, and the dialogue that takes place often generates important new insights and directions. In addition, frequent educational webinars and workshops are now offered to the broader scientific community throughout the year.

All administrative costs are kept on a reasonable level in order that much money as possible to be spent on research and the other aims of the Foundation. Less than 20% of the income of the Foundation is spent on personnel costs, about half of which is for researchers employed by the Foundation who are actively contributing to the achievement of the mission and vision, working in collaboration with the wider research community. These researchers support EQ-5D users and other researchers by providing information on data modelling, data analyses and study conduct.

For more information on the activities of the Foundation, please see the <u>2023/24 Annual Report</u>.

The Foundation invites and welcomes members of the public to make donations to support its objectives.



### 6. Testimonials

Prof. Eliza LY Wong, JC School of Public Health & Primary Care, The Chinese University of Hong Kong

We have worked very closely with the EuroQol Research Foundation over the past three years to conduct two projects on EQ-5D-5L. The Foundation has offered us an enormous support in term of staff training, technical support on quality control of data collection and expert advice on data analysis. We valued their expertise and experience. The support that we received has been great and timely. Their professional and willingness to make contribution in the area of patient's preference and quality of life made our project such a success.

Dr. Nils Gutacker, Centre for Health Economics, University of York, UK Member of the EuroQol Group

Prospective patients want to know if surgery will make them feel better. We developed an online tool to inform UK patients about the likely outcome of hip and knee surgery based on what previous patients had reported before (http://www.aftermysurgery.org.uk). This would not have been possible without the help of the EuroQol group. They gave the English NHS permission to collect the needed data using the EuroQol instrument and waived the associated fee. The intuitive format of the EuroQol instrument also makes it easy to explain the results to prospective patients. Great work!



# 7. Contact details

Stichting EuroQol Research Foundation Attn. Bernhard Slaap Executive Director

Marten Meesweg 107, 3068 AV Rotterdam, The Netherlands, Phone number: +31 882026890

Website: <a href="https://www.euroqol.org">https://www.euroqol.org</a>